Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
Merck announced pivotal Phase 3 TroFuse-005 results for sacituzumab tirumotecan (sac-TMT) in advanced or recurrent endometrial cancer, showing a 32% reduction in the risk of death and a 41% reduction in the risk of progression or death versus chemotherapy. Median overall survival was extended by 6.9 months (19.0 vs. 12.1 months) and median PFS by 3.3 months (7.2 vs. 3.9 months); ORR was 35.1% vs.
Key figures
- Drug Name
- sacituzumab tirumotecan (sac-TMT)
- Phase Of Trial
- Phase 3
- Orr tpc
- 17.3%
- Pdufa date
- June 15, 2027
- Orr sac tmt
- 35.1%
- Os hazard ratio
- 0.68
- Pfs hazard ratio
- 0.59
- Trial enrollment
- 776
- Os risk reduction
- 32%
- Pfs risk reduction
- 41%
- Median os tpc months
- 12.1
- Median pfs tpc months
- 3.9
- Median os sac tmt months
- 19
- Phase3 trials in program
- 18
- Median pfs sac tmt months
- 7.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.